Conference Coverage

Denosumab's benefits persist through 8 years

Publish date: July 2, 2014

 

AT ICE/ENDO 2014

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Breast cancer hormone therapy may affect cognitive function
MDedge Endocrinology
Hormone therapy’s protection against endometrial cancer persists in Women’s Health Initiative follow-up study
MDedge Endocrinology
No survival benefit to bisphosphonate in chemoresistant breast cancer
MDedge Endocrinology
Romosozumab boosts bone density while cutting resorption
MDedge Endocrinology
New stroke guidelines focus on women’s risks
MDedge Endocrinology
It’s time to put to rest the calcium supplement controversy
MDedge Endocrinology
Menopause doesn’t drive severe asthma
MDedge Endocrinology
Topical lidocaine reduces menopausal dyspareunia
MDedge Endocrinology
Women’s Health Initiative study netted $37 billion in savings
MDedge Endocrinology
Yearly monitoring does not predict fractures after bisphosphonate cessation
MDedge Endocrinology